Patient Benefits and Cost Savings Predicted for Mineralocorticoid-Receptor Antagonist Treatment of Early and Advanced Diabetic Kidney Disease

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.1458
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Monitoring Renal Safety in Mineralocorticoid Receptor Antagonist Trials

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2017English

Erratum. Comparison of Kidney Transcriptomic Profiles of Early and Advanced Diabetic Nephropathy Reveals Potential New Mechanisms for Disease Progression. Diabetes 2019;68:2301–2314

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2020English

Diabetic Kidney Disease

Nature Reviews Disease Primers
Medicine
2015English

Aldosterone and the Mineralocorticoid Receptor in Renal Injury: A Potential Therapeutic Target in Feline Chronic Kidney Disease

Journal of Veterinary Pharmacology and Therapeutics
VeterinaryPharmacology
2020English

Successful Pregnancy and Childbirth in a Patient With Diabetic Kidney Disease Receiving Hemodialysis

Soonchunhyang Medical Science
2012English

Current and Emerging Treatment Options for the Elderly Patient With Chronic Kidney Disease

Clinical Interventions in Aging
MedicineGerontologyGeriatrics
2014English

Significance of AT1 Receptor Independent Activation of Mineralocorticoid Receptor in Murine Diabetic Cardiomyopathy

PLoS ONE
Multidisciplinary
2014English

Managing the Diabetic Kidney Patient

Journal for Nurse Practitioners
LPNFundamentalsSkillsAdvancedLVNSpecialized Nursing
2018English

Differential Impacts of Mineralocorticoid Receptor Antagonist Potassium Canrenoate on Liver and Renal Changes in High Fat Diet-Mediated Early Hepatocarcinogenesis Model Rats

Journal of Toxicological Sciences
MedicineToxicology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy